TN-based Local Infusion Secures $10M in Series A Round Funding. Blisce led this round, with Meridian Street Capital and current investors joining onboard.
In addition to developing the business’s in-house referral and care coordination technology, the extra money will be utilised in 2024 to increase the company’s presence in New Jersey, Connecticut, and Maryland.
Read also – Aurora-based GelSana Therapeutics Secures a New Funding of Undisclosed Amount
Patients with chronic autoimmune diseases who are on specialty drugs can receive infusion therapy and comprehensive value-based care from Local Infusion. The company provides excellent, close-to-home infusion centres and individualised virtual care to patients with persistent illnesses like multiple sclerosis, rheumatoid arthritis, and Crohn’s disease.
By providing night and weekend scheduling, financial counselling, private infusion suites, and round-the-clock access to a committed care staff, Local Infusion’s revolutionary care model prioritises the requirements of its patients while also drastically lowering total healthcare costs.
Read also – Johnson & Johnson MedTech Acquires Laminar, Inc
Sam Giber, General Partner & Managing Director of Blisce US said, “Infusion care remains one the last segments in healthcare where Value Based Care has yet to fully take hold. Local Infusion is changing that through its comprehensive care model that addresses symptoms and patient care beyond the four walls of the infusion center,”.
Woody Baum, Founder & CEO of Local Infusion said, “After nearly a year in operation, with locations across Maine and New Hampshire, we have proven that our innovative patient care model delivers better outcomes — with industry leading patient satisfaction, improved medication adherence, and the lowest referral to treatment, all while saving each patient on average over $40,000 per year, With this capital, we’re replicating our care model across the Northeast U.S., building out our leadership team, and investing in referral and care coordination technology.”
Scott Law, Meridian Street Capital’s general partner said, “Local Infusion’s care delivery model has had an immediate impact in New England by lowering the cost of infusion therapy while providing an industry best patient satisfaction score. This funding will allow the company to accelerate growth to other markets where patients are underserved,”.
About Local Infusion
Because patients should receive better care, local infusion is setting the standard for managing chronic conditions. It seeks to enhance patient outcomes, free up time for doctors, and lower the cost of infusion therapy for all parties.
Read also – Boston INNO4 Secures an Investment from ServicePoint
Setting a new benchmark for the industry, Local Infusion is saving an average of $40K per patient year and boasting an industry-leading patient satisfaction NPS of 98+.
